Clinical Trials Logo

Acute Kidney Failure clinical trials

View clinical trials related to Acute Kidney Failure.

Filter by:

NCT ID: NCT01275729 Completed - Clinical trials for Acute Kidney Failure

The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury

Start date: December 2010
Phase: N/A
Study type: Interventional

The primary objective is to safely determine if the investigators can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled the investigators will draw blood and urine for novel and standard biomarkers. The investigators are attempting to determine if these biomarkers can forecast the course of AKI (need for dialysis, death and renal recovery). The investigators seek to determine how well physicians caring for those with AKI can predict the clinical course compared to these novel biomarkers of AKI and if there is an association between clinical course and 3 year patient outcomes.

NCT ID: NCT01122225 Active, not recruiting - Clinical trials for Acute Kidney Failure

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

NESAKI
Start date: July 2009
Phase: N/A
Study type: Observational

Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

NCT ID: NCT00947479 Recruiting - Clinical trials for Obstructive Sleep Apnea

Effect of Obstructive Sleep Apnea on Central Blood Pressure and Kidney and Endothelial Function

OSA-AKI
Start date: February 2009
Phase: N/A
Study type: Interventional

Obstructive sleep apnea (OSA) is a frequently underdiagnosed condition that has emerged as an increasing medical problem with important social and financial implications worldwide. OSA is a well established risk factor for systemic hypertension myocardial infarction or stroke and it has been documented that blood pressure rises in a very consistent fashion during apneic episodes. The incidence of the episodes of apnea during sleep causes repeated subclinical acute kidney injuries (AKI) contributing to the development of CKD. One of the mechanisms responsible for AKI might be endothelial injury followed by an increase of central aortic pressure.

NCT ID: NCT00890214 Completed - Clinical trials for Acute Kidney Failure

Prostacyclin's Effect on Platelet Responsiveness

Start date: September 2007
Phase: Phase 4
Study type: Interventional

The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.

NCT ID: NCT00877370 Completed - Clinical trials for Acute Kidney Failure

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.

NCT ID: NCT00760591 Recruiting - Clinical trials for Acute Kidney Failure

Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)

Start date: September 2008
Phase: N/A
Study type: Observational

Oral phosphate purgative is the preferred bowel regimen on the basis of better tolerability, cost effectiveness, and efficacy. There are also numerous reports of patients with even previously normal renal function developing acute and chronic kidney disease after use of oral phosphate purgative. Several uncontrolled case reports and case series suggest a potential link between oral phosphate and acute kidney injury and/or chronic kidney disease1. Its use is contraindicated in patients with preexisting renal disease because of the risk for developing acute renal failure, so called acute phosphate nephropathy, or electrolyte disturbance. Since most of the outpatients who are going to undergo a colonoscopy are exposed to this agent, it is important to detect or prevent vulnerable patients. We would seek a sensitive and rapid diagnosis method of acute kidney injury following sodium phosphate bowel preparation. Within a few hours, NGAL mRNA is highly upregulated after kidney injury, such as renal ischemia-reperfusion and cisplatin nephropathy, NGAL induction precedes the elevation of classical markers for kidney damage such as serum creatinine. The investigators will investigate the change of NGAL following sodium phosphate bowel preparation.

NCT ID: NCT00736866 Completed - Clinical trials for Acute Kidney Failure

The Acetylcysteine for Contrast-Induced Nephropathy Trial

ACT
Start date: August 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures that use contrast. Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure.

NCT ID: NCT00673244 Completed - Clinical trials for Acute Kidney Failure

Protocol to Assess the Severity of Acute Kidney Injury

AKI
Start date: April 2008
Phase: N/A
Study type: Interventional

The principal objective is to safely determine if we can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled, we will draw blood and urine for relevant biomarkers. Our goal is to validate if any of these biomarkers can predict the course of AKI (recovery v. RRT v. death)

NCT ID: NCT00529139 Completed - Clinical trials for Acute Kidney Failure

Hannover Dialysis Outcome Study

HAND-OUT
Start date: July 2003
Phase: Phase 4
Study type: Interventional

Mortality rates of patients with acute kidney injury in the intensive care unit have changed little over the past few decades despite significant advances in supportive care. Few interventions have been shown to result in an improvement of in-hospital mortality of these patients, with dose of renal replacement therapy (RRT) being one of the most important. Patients undergoing continuous veno-venous hemofiltration had better outcomes with ultrafiltration rates of 35 mL/kg/h or 45 mL/kg/h than those treated at a rate of 20 mL/kg/h. In a different trial, intermittent hemodialysis on a daily basis resulted in better control of uremia, fewer hypotensive episodes during dialysis, and more rapid resolution of acute renal failure than thrice weekly hemodialysis. In the present study we examine survival and renal recovery in critically ill patients with acute kidney injury that are treated with a currently recommended (standard) dose of RRT, and patients that receive intensified RRT.

NCT ID: NCT00472563 Completed - Clinical trials for Acute Kidney Failure

Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

PROMEC
Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the risk of kidney injury after contrast medium exposition. We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.